FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017441789> ?p ?o ?g. }

• W2017441789 endingPage "204" @default.
• W2017441789 startingPage "188" @default.
• W2017441789 abstract "Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membrane receptor signaling.In recent years, the PI3K/AKT/mTOR pathway, which transmits signals from the cell membrane into the nucleus and activates multiple oncogenic programs, has been found to play a crucial role in the regulation of breast cancer cell growth. This pathway is densely interconnected with a multitude of other important regulatory systems for glucose-,lipid- and amino acid-metabolism, for energy balance, and for autophagy. It has been found that PI3K/AKT/mTOR signaling modulates estrogen receptor function. Using transverse and feedback regulatory loops the PI3K/AKT/mTOR cascade can communicate with concurrent and with upstream systems. Thus, PI3K/AKT/mTOR is a crucial element within a complicated signaling network. This pathway is hyperactive in more than 70% of breast tumors. Hence, the protein kinases located along this route represent very attractive and promising drug targets for breast cancer therapy. Currently, numerous small molecular drugs that inhibit PI3K, AKT and/or mTOR are being developed in preclinical and clinical models of breast cancer. Some of these compounds are highly selective blocking only one particular kinase complex, whereas others interfere with two (mTORC1+mTORC2) or even three effectors (PI3K+mTORC1+mTORC2) of the pathway. Due to the many interactions with other regulatory systems, silencing of the pathway can cause unexpected results. Therefore, detailed preclinical and clinical evaluation of these compounds as single drugs and in combination is required to achieve optimal results with maximal clinical benefit and acceptable toxicity. Also, reliable biomarkers for the identification of patient subsets that will maximally benefit from PI3K/AKT/mTOR inhibition need to be developed. Thus, selective silencing of PI3K/AKT/mTOR signaling represents a promising approach for breast cancer and might prove useful when combined with other drugs. Here we review the current preclinical and clinical data and compare the potential benefits of multi- versus single-targeting PI3K/AKT/mTOR drugs." @default.
• W2017441789 created "2016-06-24" @default.
• W2017441789 creator A5048876485 @default.
• W2017441789 creator A5053156873 @default.
• W2017441789 date "2013-03-01" @default.
• W2017441789 modified "2023-09-23" @default.
• W2017441789 title "Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling" @default.
• W2017441789 cites W1562190372 @default.
• W2017441789 cites W1565276921 @default.
• W2017441789 cites W1585517331 @default.
• W2017441789 cites W1606526901 @default.
• W2017441789 cites W1946355969 @default.
• W2017441789 cites W1967405376 @default.
• W2017441789 cites W1969644543 @default.
• W2017441789 cites W1976537305 @default.
• W2017441789 cites W1976559692 @default.
• W2017441789 cites W1978301900 @default.
• W2017441789 cites W1980870530 @default.
• W2017441789 cites W1986234170 @default.
• W2017441789 cites W1988338260 @default.
• W2017441789 cites W1988643126 @default.
• W2017441789 cites W1992137818 @default.
• W2017441789 cites W1992257057 @default.
• W2017441789 cites W1996861095 @default.
• W2017441789 cites W1998641189 @default.
• W2017441789 cites W2001099495 @default.
• W2017441789 cites W2001568034 @default.
• W2017441789 cites W2004688803 @default.
• W2017441789 cites W2006463960 @default.
• W2017441789 cites W2010501725 @default.
• W2017441789 cites W2010601523 @default.
• W2017441789 cites W2011810742 @default.
• W2017441789 cites W2011961482 @default.
• W2017441789 cites W2013066520 @default.
• W2017441789 cites W2014001512 @default.
• W2017441789 cites W2017289276 @default.
• W2017441789 cites W2020372547 @default.
• W2017441789 cites W2021837129 @default.
• W2017441789 cites W2022742795 @default.
• W2017441789 cites W2023561125 @default.
• W2017441789 cites W2026138332 @default.
• W2017441789 cites W2029376575 @default.
• W2017441789 cites W2029882446 @default.
• W2017441789 cites W2031469256 @default.
• W2017441789 cites W2038233152 @default.
• W2017441789 cites W2041811289 @default.
• W2017441789 cites W2044867944 @default.
• W2017441789 cites W2044874695 @default.
• W2017441789 cites W2046410395 @default.
• W2017441789 cites W2051066612 @default.
• W2017441789 cites W2054541910 @default.
• W2017441789 cites W2055614052 @default.
• W2017441789 cites W2056183265 @default.
• W2017441789 cites W2058725749 @default.
• W2017441789 cites W2069232844 @default.
• W2017441789 cites W2070841378 @default.
• W2017441789 cites W2072208907 @default.
• W2017441789 cites W2073090360 @default.
• W2017441789 cites W2076203883 @default.
• W2017441789 cites W2077223675 @default.
• W2017441789 cites W2078358665 @default.
• W2017441789 cites W2082888699 @default.
• W2017441789 cites W2086589626 @default.
• W2017441789 cites W2087821275 @default.
• W2017441789 cites W2089738145 @default.
• W2017441789 cites W2090756832 @default.
• W2017441789 cites W2091906158 @default.
• W2017441789 cites W2095156669 @default.
• W2017441789 cites W2097000222 @default.
• W2017441789 cites W2097255042 @default.
• W2017441789 cites W2099019742 @default.
• W2017441789 cites W2101844536 @default.
• W2017441789 cites W2104795646 @default.
• W2017441789 cites W2109439031 @default.
• W2017441789 cites W2111607026 @default.
• W2017441789 cites W2112911113 @default.
• W2017441789 cites W2113458582 @default.
• W2017441789 cites W2115950635 @default.
• W2017441789 cites W2118073504 @default.
• W2017441789 cites W2119060677 @default.
• W2017441789 cites W2121917721 @default.
• W2017441789 cites W2128677683 @default.
• W2017441789 cites W2130315090 @default.
• W2017441789 cites W2134757689 @default.
• W2017441789 cites W2135159262 @default.
• W2017441789 cites W2135372494 @default.
• W2017441789 cites W2136262447 @default.
• W2017441789 cites W2141300809 @default.
• W2017441789 cites W2142105072 @default.
• W2017441789 cites W2142506125 @default.
• W2017441789 cites W2144191082 @default.
• W2017441789 cites W2146024986 @default.
• W2017441789 cites W2146384083 @default.
• W2017441789 cites W2148029969 @default.
• W2017441789 cites W2148823465 @default.
• W2017441789 cites W2149773268 @default.
• W2017441789 cites W2149840294 @default.
• W2017441789 cites W2150981403 @default.

• next